Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 69.26 | 72.05 | 89.99 | 92.55 | 78.46 | 84.60 | 89.11 | 82.50 | 81.37 | 94.78 | 75.14 | 72.94 |
| Expenses | 61.33 | 62.75 | 78.63 | 76.27 | 69.89 | 71.85 | 81.69 | 70.79 | 67.79 | 80.73 | 70.98 | 63.82 |
| Operating Profit | 7.93 | 9.30 | 11.36 | 16.28 | 8.57 | 12.75 | 7.42 | 11.71 | 13.58 | 14.05 | 4.16 | 9.12 |
| OPM % | 11.45% | 12.91% | 12.62% | 17.59% | 10.92% | 15.07% | 8.33% | 14.19% | 16.69% | 14.82% | 5.54% | 12.50% |
| Other Income | 0.27 | 0.58 | 2.36 | 0.44 | 2.04 | 0.06 | 2.34 | 1.00 | 0.42 | 0.18 | 2.01 | 0.46 |
| Interest | 2.81 | 2.34 | 2.84 | 2.40 | 2.14 | 2.14 | 2.03 | 1.87 | 1.62 | 1.54 | 1.42 | 1.90 |
| Depreciation | 3.73 | 3.73 | 3.78 | 3.68 | 3.76 | 3.76 | 3.80 | 3.82 | 3.89 | 3.91 | 3.85 | 4.24 |
| Profit before tax | 1.66 | 3.81 | 7.10 | 10.64 | 4.71 | 6.91 | 3.93 | 7.02 | 8.49 | 8.78 | 0.90 | 3.44 |
| Tax % | 126.51% | -8.14% | 8.73% | 33.27% | 29.72% | 29.81% | 11.45% | 37.61% | 24.38% | 24.26% | 62.22% | 46.51% |
| Net Profit | -0.44 | 4.12 | 6.47 | 7.10 | 3.30 | 4.86 | 3.48 | 4.39 | 6.42 | 6.65 | 0.35 | 1.84 |
| EPS in Rs | 2.25 | 14.22 | 19.52 | 23.15 | 15.45 | 18.09 | 9.82 | 13.76 | 20.18 | 21.90 | 1.46 | 8.77 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 261 | 266 | 350 | 316 | 306 | 345 | 334 | 324 |
| Expenses | 343 | 235 | 235 | 316 | 287 | 275 | 300 | 289 | 283 |
| Operating Profit | 35 | 25 | 30 | 35 | 29 | 31 | 45 | 45 | 41 |
| OPM % | 9% | 10% | 11% | 10% | 9% | 10% | 13% | 13% | 13% |
| Other Income | 2 | 2 | 2 | 14 | 5 | 4 | 5 | 2 | 3 |
| Interest | 6 | 5 | 5 | 6 | 7 | 10 | 9 | 6 | 6 |
| Depreciation | 6 | 8 | 8 | 10 | 11 | 15 | 15 | 15 | 16 |
| Profit before tax | 25 | 15 | 20 | 33 | 17 | 10 | 26 | 25 | 22 |
| Tax % | 30% | 31% | 31% | 23% | 31% | 36% | 28% | 29% | |
| Net Profit | 18 | 10 | 14 | 25 | 11 | 6 | 19 | 18 | 15 |
| EPS in Rs | 59.04 | 33.67 | 44.85 | 83.75 | 37.91 | 30.07 | 66.52 | 57.26 | 52.31 |
| Dividend Payout % | 3% | 0% | 3% | 2% | 4% | 5% | 2% | 3% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 5% | 2% | -3% | ||
| Compounded Profit Growth | % | 5% | 20% | -8% | ||
| Stock Price CAGR | % | 15% | 42% | 32% | ||
| Return on Equity | % | 8% | 8% | 8% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 103 | 113 | 126 | 149 | 166 | 174 | 194 | 211 |
| Borrowings | 47 | 65 | 65 | 80 | 100 | 101 | 86 | 111 |
| Other Liabilities | 116 | 72 | 108 | 125 | 126 | 114 | 107 | 130 |
| Total Liabilities | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 |
| Fixed Assets | 118 | 124 | 130 | 142 | 228 | 223 | 232 | 268 |
| CWIP | 3 | 16 | 38 | 51 | 1 | 6 | 0 | 10 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 148 | 113 | 134 | 164 | 166 | 162 | 158 | 176 |
| Total Assets | 270 | 253 | 302 | 357 | 395 | 391 | 390 | 454 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 30 | 15 | 35 | -11 | 15 | 24 | 34 | 37 |
| Cash from Investing Activity | -44 | -27 | -26 | -7 | -31 | -18 | -15 | -58 |
| Cash from Financing Activity | 15 | 12 | -3 | 11 | 17 | -7 | -19 | 21 |
| Net Cash Flow | 1 | -0 | 6 | -8 | 0 | -1 | -0 | 1 |
| Free Cash Flow | 6 | -9 | -0 | -53 | -28 | 4 | 19 | -21 |
| CFO/OP | 105% | 69% | 133% | -10% | 62% | 88% | 94% | 98% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 40 | 30 | 47 | 35 | 53 | 61 | 73 | 67 |
| Inventory Days | 116 | 149 | 164 | 159 | 184 | 196 | 160 | 210 |
| Days Payable | 140 | 101 | 163 | 146 | 127 | 143 | 126 | 162 |
| Cash Conversion Cycle | 16 | 78 | 48 | 48 | 110 | 115 | 106 | 116 |
| Working Capital Days | 14 | 18 | 2 | 17 | 24 | 11 | 7 | 5 |
| ROCE % | 12% | 13% | 12% | 8% | 7% | 12% | 10% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 70.32% | 70.68% | 71.19% | 71.40% | 71.40% | 71.40% | 71.40% | 71.40% | 71.40% | 71.79% | 72.10% | 72.10% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.01% | 0.02% | 0.00% | 0.00% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.03% | 0.29% | 0.30% | 0.31% |
| Public | 29.68% | 29.31% | 28.81% | 28.59% | 28.57% | 28.59% | 28.60% | 28.56% | 28.57% | 27.91% | 27.59% | 27.58% |
| No. of Shareholders | 8,443 | 8,233 | 8,116 | 7,861 | 7,849 | 7,626 | 7,479 | 7,412 | 7,521 | 7,125 | 6,937 | 6,859 |
Fundamentals
Market Cap₹ 449 Cr.
Current Price₹ 1,488
Stock P/E28.4
Book Value₹ 706
ROCE9.91 %
ROE8.44 %
Dividend Yield0.10 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-3%
Compounded Profit Growth (TTM)-8%
Consolidated figures.
Valuation
Market capRs 450 Cr
Enterprise valueRs 550 Cr
P/E (TTM)28.49x
Price to book2.55x
Price to sales1.39x
EV / EBITDA12.50x
EV / EBIT19.57x
EV / sales1.70x
Price to cash flow18.53x
Earnings yield3.51%
Dividend yield0.10%
P/E, 3-year average14.76x
P/B, 3-year average1.15x
P/E, 5-year average12.11x
P/B, 5-year average1.02x
Profitability
Operating margin (excl. other income)10.20%
Operating margin (incl. other income)11.45%
EBITDA margin13.56%
Pre-tax margin6.67%
Net profit margin4.88%
Net margin, latest quarter3.63%
ROE5.26%
ROCE7.35%
ROA2.31%
ROE, 3-year average10.13%
ROCE, 3-year average11.67%
ROA, 3-year average4.35%
ROE, 5-year average10.13%
ROCE, 5-year average11.96%
ROA, 5-year average4.37%
ROIC (approx.)6.54%
Tax rate35.77%
Other income / net worth2.17%
Growth
Sales growth (latest year)-3.04%
Profit growth (latest year)-20.68%
Sales CAGR, 3 years4.83%
Sales CAGR, 5 years-4.13%
Profit CAGR, 3 years-12.48%
Profit CAGR, 5 years-12.63%
Sales growth QoQ-2.93%
Profit growth QoQ502.27%
Sales growth YoY (latest quarter)-11.59%
Profit growth YoY (latest quarter)-36.30%
Per share
EPS (TTM)Rs 52.29
EPS (latest year)Rs 30.07
EPS (latest quarter)Rs 8.77
EPS, 3-year averageRs 50.57
EPS, 5-year averageRs 46.05
Book value per shareRs 584.83
Sales per shareRs 1,072.44
Cash flow per shareRs 80.41
Free cash flow per shareRs -69.46
Dividend per share (latest year)Rs 1.49
Dividend per share, 3-year averageRs 1.49
Dividend per share, 5-year averageRs 1.49
Dividends
Dividend payout4.95%
Dividend payout, 3-year average3.55%
Dividend payout, 5-year average3.49%
Efficiency
Asset turnover0.78x
Fixed asset turnover1.37x
Inventory turnover2.57x
Inventory days142 days
Debtor days61 days
Debtors turnover5.96x
Creditor days162 days
Cash conversion cycle116 days
Working capital days5 days
Leverage
Total debtRs 101 Cr
Cash and bankRs 1 Cr
Net debtRs 99 Cr
Debt to equity0.57x
Net debt / EBITDA2.26x
Interest coverage4.33x
Owners' fund to total sources45.18%
Debt to assets25.74%
Cash flow
Cash from Operating Activity (latest year)Rs 24 Cr
Cash from Investing Activity (latest year)Rs -18 Cr
Cash from Financing Activity (latest year)Rs -7 Cr
Net Cash Flow (latest year)Rs -1 Cr
Free cash flow (latest year)Rs -21 Cr
FCFE (approx.: FCF + change in debt)Rs -21 Cr
Cash from ops / profit, 5 years1.25x
Sales to cash flow12.59x
Statement figures
Net sales (TTM)Rs 324 Cr
Net sales (latest year)Rs 306 Cr
Sales (latest quarter)Rs 73 Cr
Operating profit excl. other income (latest year)Rs 31 Cr
Operating profit (latest quarter)Rs 9 Cr
Other income (TTM)Rs 3 Cr
EBITDA (TTM)Rs 44 Cr
PBDT (TTM)Rs 38 Cr
Profit before tax (TTM)Rs 22 Cr
Tax (latest year)Rs 4 Cr
Net profit (TTM)Rs 16 Cr
Net profit (latest year)Rs 9 Cr
Net profit (latest quarter)Rs 3 Cr
Depreciation (TTM)Rs 16 Cr
Depreciation (latest quarter)Rs 4 Cr
Interest (TTM)Rs 6 Cr
Cost of goods sold (latest year)Rs 209 Cr
Total expenditure (latest year)Rs 275 Cr
Total income (latest year)Rs 310 Cr
Share capitalRs 3 Cr
ReservesRs 174 Cr
Shareholders' fundsRs 177 Cr
Total assetsRs 391 Cr
Net blockRs 223 Cr
Capital work in progressRs 6 Cr
InvestmentsRs 0 Cr
ReceivablesRs 51 Cr
InventoryRs 81 Cr
Other liabilitiesRs 114 Cr
Shares outstanding (crore)0.30
Ownership
Promoter holding72.10% (+0.70 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 28.5 is at the 97th percentile of its own 5.4-year range
(median 16.2, low 10.1, high 28.7).
P/B 2.55 is at the 85th percentile (median 2.03).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | HALEOSLABS | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -0.9% | -2.8% | +1.9 pts |
| 1 month | +0.7% | -6.8% | +7.5 pts |
| 3 months | -8.6% | -7.6% | -1.0 pts |
| 6 months | +19.9% | +0.4% | +19.5 pts |
| 1 year | +22.6% | -9.9% | +32.6 pts |
| 2 years | +0.3% | -13.6% | +13.9 pts |
| 3 years | +188.2% | +14.2% | +174.0 pts |
| 5 years | +102.1% | +27.9% | +74.2 pts |
Red flags
F-score 5 of 8No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹73 Cr -11.6% vs Jun 2025.
Net profit ₹2 Cr -58.1%.
Against our estimate for Jun 2026: sales -9.9%, profit -63.2% miss. Our estimate for Sep 2026: sales Rs 70 Cr, profit Rs 3 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-09-23 | Dividend - Rs 1.50 Per Share | |
| 2025-09-24 | Dividend - Rs 1.50 Per Share | |
| 2024-09-23 | Annual General Meeting/Dividend - Rs 1.50 Per Share | |
| 2023-09-22 | Annual General Meeting/Dividend - Rs 1.50 Per Share | |
| 2022-09-22 | Annual General Meeting/Dividend - Rs 1.50 Per Share | |
| 2021-09-20 | Annual General Meeting/Dividend - Rs 1.50 Per Share | |
| 2019-09-19 | Dividend - Rs 1.50 Per Share | |
| 2018-09-12 | Annual General Meeting |
| Date | Type | What it says |
|---|---|---|
| 2026-10-01 | Shareholder meeting | Voting results. |
| 2026-09-30 | Shareholder meeting | Proceedings of Annual General Meeting held on September 30, 2026 |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 days
Quick answers
What is the market cap of Haleos Labs Limited?
Haleos Labs Limited (HALEOSLABS) has a market capitalisation of Rs 449 Cr. at the 2026-10-01 close.
What is the P/E ratio of Haleos Labs Limited?
Haleos Labs Limited trades at a P/E of 28.4 on trailing twelve-month profit, at the 2026-10-01 close.
What were Haleos Labs Limited's latest quarterly results?
In the Jun 2026 quarter, Haleos Labs Limited sales was Rs 73 Cr (-11.6% vs Jun 2025) and net profit was Rs 2 Cr.
What is the 52-week high and low of Haleos Labs Limited?
The 52-week high is Rs 1,774.00 and the 52-week low is Rs 1,091.10.